While specific IL-5-targeting agents have failed to achieve meaningful improvement in AD [32], they have been shown to reduce eosinophil counts and ameliorate allergic rhinitis symptoms in asthma [33,34]. The gene discussed is IL5; the disease is Alzheimer disease.